|
1.
|
Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al.
ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases
developed in collaboration with the EASD. European Heart Journal.
2013;34(39):3035-3087. doi:10.1093/eurheartj/eht108.
|
|
2.
|
Centers for Disease Control and Prevention. Prediabetes. CDC; 2022. Available at: https://www.cdc.gov/diabetes/b
sics/prediabetes.html. Accessed March 16, 2022.
|
|
3.
|
Bansal N. Prediabetes diagnosis and treatment: A review. World Journal of Diabetes. 2015;6(2):296-303. doi:10.4239/jd.v6.i2.296.
|
|
4.
|
Brannick B, Dagogo-Jack S. Prediabetes and cardiovascular disease: pathophysiology and interventions for prevention and
risk reduction. Endocrinology and Metabolism Clinics of North America. 2018;47(1):33-50. doi:10.1016/j.ecl.2017.10.001.
|
|
5.
|
Merck. Glucophage® XR Prescribing Information. May 2016.
|
|
6.
|
Hostalek U, Ametov A, Barykina I, Bondar I, Vaysberg A, Verbovaya N, Zhukova L, Zamyatina O, Kiseleva T, Morugova T,
Shabalina E, Hildemann S. Multicentre evaluation of adherence to extended-release metformin in daily practice in Russia.
International Journal of Diabetes and Clinical Research. 2017;4:078. doi:10.23937/2377-3634/1410078.
|
|
7.
|
Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets
compared to immediate-release metformin tablets: results of a retrospective cohort study. Current Medical Research and
Opinion. 2004;20(4):565-572. doi:10.1185/030079904125003278.
|
|
8.
|
American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: Standards of
Medical Care in Diabetes—2022. Diabetes Care. 2022;45(Suppl 1):S17-S38. doi:10.2337/dc22-S002.
|
|
9.
|
Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or
metformin. New England Journal of Medicine. 2002;346(6):393-403. doi:10.1056/NEJMoa012512.
|
